Holen Sie sich die Stockscreener-App
6.00
1.18%
0.07
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
High Insider Ownership Growth Stocks To Watch In August 2026 - simplywall.st
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone - Yahoo Finance
Abeona (ABEO) Latest Quarter: EPS Misses Its Estimate in the Latest Session; Market Reaction: The Market Price Declines 2.77% for the Current SessionRevenue Growth Outlook - vinanet.vn
Abeona (ABEO) Q2 2026 Earnings Call Transcript - AOL.com
ABEO: Zevaskyn Launch Gains Momentum - Smartkarma
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlight - GuruFocus
Abeona Therapeutics (ABEO) Q2 Revenue Misses Estimates; Market Pricing Reflects Growth Uncertainty - GuruFocus
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ... - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Understanding the Setup: (ABEO) and Scalable Risk - Stock Traders Daily
Abeona Therapeutics Insiders Sell US$2.9m Of Stock, Possibly Signalling Caution - Moomoo
Abeona Therapeutics Stock Price Forecast. Should You Buy ABEO? - StockInvest.us
Montanova Capital (ABEO) reports 0.9% beneficial stake in Abeona Therapeutics - Stock Titan
ABEO Maintained by Oppenheimer -- Price Target Lowered to $21.00 - GuruFocus
Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating - marketscreener.com
Abeona Therapeutics (ABEO) Q2 2026 Earnings Call: ZEVASKYN Revenue Rises 31% - TradingKey
Abeona Therapeutics (ABEO) Stock Faces Early Launch Strain Despite Revenue Traction - Sahm
Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Abeona Therapeutics: Earnings Sell-Off Could Be A Buy Opportunity (NASDAQ:ABEO) - Seeking Alpha
Abeona Therapeutics (NASDAQ:ABEO) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Abeona Therapeutics Shares Fall After Q2 Miss - marketscreener.com
Abeona Therapeutics (ABEO) Advances ZEVASKYN Rollout Amid Mixed Valuation Signals - GuruFocus
Transcript : Abeona Therapeutics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Abeona Therapeutics Q2 Results: Revenue Rises 31% QoQ To $11.4 Million - scanx.trade
Abeona Therapeutics (ABEO) Stock Dips After Q2 Miss; Price-to-Sa - GuruFocus
Abeona Therapeutics Down Nearly 15%, On Pace For Largest Percent Decrease Since April 2024 -- Data Talk - Moomoo
Abeona Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
Abeona Therapeutics Q2 Earnings Call Highlights - MarketBeat
Abeona stock drops after Q2 revenue miss (ABEO:NASDAQ) - Seeking Alpha
Earnings call transcript: Abeona Therapeutics misses Q2 2026 revenue view as shares fall - Investing.com
Abeona Therapeutics Reports Q2 2026 Results in Form 10-Q Filing - Kalkine Media
Abeona Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why is Abeona Therapeutics stock slumping today? By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Q2 Earnings Highlight Challenges Amid Soaring Price-to-Sales Ratio - GuruFocus
Is Abeona Therapeutics Inc (ABEO) Facing Sustainability Challeng - GuruFocus
Abeona Therapeutics: Q2 Earnings Snapshot - AOL.com
ABEONA THERAPEUTICS INC. Q2 2026: Revenue $11.38M, EPS $(0.35) — 10-Q Summary - TradingView
Abeona Therapeutics Q2 net loss widens, misses analyst expectations - TradingView
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update - The Manila Times
Abeona Q2 Revenue Rises 31% to $11.4 Million - Quiver Quantitative
Abeona Therapeutics reports Q2 2026: $11.4M product revenue, $20.2M net loss - TradingView
Abeona Therapeutics (ABEO) grows ZEVASKYN sales but records H1 2026 net loss - Stock Titan
Abeona Q2 FY26 net loss widens to $20.2 million; revenue rises 31% Q/Q to $11.4 million - Bitget
Abeona Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Weekly Recap: CMS NTAP for ZEVASKYN and Q2 2026 results call - TradingView
Abeona will stream its Q2 financial update on Aug. 13 - Stock Titan
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 - GlobeNewswire
Abeona Therapeutics (ABEO) Projected to Announce Earnings on Thursday - MarketBeat
The Technical Signals Behind (ABEO) That Institutions Follow - Stock Traders Daily
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Abeona Therapeutics’ gene therapy receives Medicare payment status - Investing.com
Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics’ gene therapy receives Medicare payment status By Investing.com - Investing.com South Africa
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN® - The Manila Times
A new CMS payment could help Medicare patients access ZEVASKYN - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Two Abeona New Hires Receive Awards Vested Over Three Years - Stock Titan
Abeona Therapeutics Inc (ABEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Abeona Therapeutics Inc (ABEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Abeona Therapeutics Inc (ABEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Law firm probes Abeona Therapeutics for possible director breaches harming shareholders. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) - PR Newswire
Abeona Therapeutics Inc (ABEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ABEO|Abeona Therapeutics Inc|Price:6.050|Chg%:-0.330 - TradingKey
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):